title: Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats.
abstract: Cisplatin is one of the most common chemotherapeutic drugs used against various solid, tumours. Despite of its therapeutic benefits, its use in clinical practice is often limited because of dose, related toxicity. The nephrotoxic potential of cisplatin has been ascribed to its accumulation in the, renal tubular cells generating reactive oxygen species (ROS), activation of Bax, increased secretion of, TNFα and activation of certain inflammatory mediators like cytokines. The present investigation was, undertaken with an objective to study the effect of rosiglitazone against cisplatin induced, nephrotoxicity. Pretreatment of rosiglitazone prevents cisplatin induced nephrotoxicity which was, clearly evident from the renal biochemical parameters like reduced BUN, creatinine and TNFα levels, and increased albumin levels, which was also supported by histopathological studies of the kidneys. In contrast, posttreatment of rosiglitazone was not able to protect the renal damage in cisplatin induced, renal toxicity. These results showed the variation of pre & posttreatment effects of rosiglitazone, against the cisplatin induced nephrotoxicity.
authors.affiliation: Laboratory of Molecular Pharmacology and Toxicology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, GMCH, Bhangagarh, Guwahati, Assam, India. Electronic address: parveen5niper@gmail.com.
authors.forename: Parveen
authors.initials: P
authors.lastname: Kumar
authors.forename: Krishna Shastrula
authors.initials: KS
authors.lastname: Prashanth
authors.forename: Anil Bhanudas
authors.initials: AB
authors.lastname: Gaikwad
authors.forename: Mohit
authors.initials: M
authors.lastname: Vij
authors.forename: Chandana C
authors.initials: CC
authors.lastname: Barua
authors.forename: Babul
authors.initials: B
authors.lastname: Bezbaruah
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology; D007677:Kidney Function Tests; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077154:Rosiglitazone; D012709:Serum Albumin / Q000032:analysis; D045162:Thiazolidinediones / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D012709:Serum Albumin; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077154:Rosiglitazone; D003404:Creatinine; D002945:Cisplatin
keywords: Cisplatin; Inflammation; Nephrotoxicity; Posttreatment; Pretreatment; Rosiglitazone